Dennis Wegener
Papers
1
Total Citations
3
H-Index
1
About
Dennis Wegener is a pioneer in the integration of miniaturized synthesis and screening for preclinical drug discovery, with a particular focus on robotic automation and microfluidics. His most cited work, a 2013 case study on the identification of histone deacetylase inhibitors, demonstrates a transformative approach to pharmaceutical development. Wegener recognized that traditional drug development suffers from a critical bottleneck: the separation of library synthesis and biological screening, which necessitates complex and costly compound storage facilities. By developing a robotic alliance that merges these two processes into a seamless, miniaturized workflow, he eliminated the need for intermediate storage, dramatically accelerating the hit-to-lead pipeline. This work, which has garnered 3 citations, serves as a foundational proof-of-concept for integrated drug discovery platforms. Wegener’s contributions are especially notable for their practical impact on reducing compound degradation and handling errors, making high-throughput screening more efficient and reliable. His research continues to inspire innovations in automated synthesis and real-time biological testing, positioning him as a key figure in the evolution of modern pharmaceutical engineering.
Research Focus
Key Achievements
Top Papers
- 1